NCT00640627

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 380 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Conditions

• Osteoarthritis, Knee

Interventions

Type	Name	Description
DRUG	Celecoxib	200 mg oral capsule once daily for 6 weeks
DRUG	Placebo	Matched oral placebo for 6 weeks

Timeline

• Start date: 2003-12-01
• Completion: 2004-09-01
• First posted: 2008-03-21
• Last updated: 2021-02-02

Locations

30 sites across 1 country: United States